Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nasdaq-listed company Dendreon has received approval from FDA to commence sales of its Provenge immunotherapy vaccine for the treatment of prostate cancer.
Subscribe to our email newsletter
Dendreon plans to have three plants to make Provenge by mid of 2011. According to an estimate by Bloomberg the drug is expected to generate $1.2bn by 2014.
Dendreon is using cancer immunotherapies that use the patient’s own immune system to treat cancer and the approval of Provenge represents a scientific and clinical advancement for the treatment of prostate cancer.
Prima BioMed, an Australian biotechnology firm focused on cancer immunotherapy, is using the technology to develop its CVac immunotherapy cancer vaccine for the treatment of ovarian cancer.
Prima BioMed said that the approval of Provenge represents a transformational event in the development of cancer treatments and is expected to create a new treatment paradigm for patients with cancer.